Preclinical and clinical data indicate distinct therapeutic vulnerabilities across SCLC subtypes: SCLC-A exhibits variable sensitivity to platinum-based agents, alongside potential responses to BCL2 inhibitors and DLL3-targeted therapies. Here, BCL2 is linked to small cell lung carcinoma.